US · Healthcare · Biotechnology
EPS came in at -0.04 against a street estimate of -0.07 — a beat of 42.9%.
Analysts rate iBio, Inc. Common Stock a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $5.53.
| Fund | Stake |
|---|---|
| Affinity Asset Advisors, LLC | 13.34% |
| Frazier Life Sciences Management, L.P. | 6.50% |
| Millennium Management LLC | 5.50% |
| Citadel Advisors Llc | 4.61% |
| Vanguard Capital Management, LLC | 3.62% |
| Balyasny Asset Management LLC | 3.36% |
| Ikarian Capital, LLC | 3.18% |
| Sio Capital Management, LLC | 3.01% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for iBio, Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.